Electrocardiographic method for identifying moxifloxacin-induced ventricular repolarization abnormalities

We developed a new technique for the measurements of repolarization abnormalities from surface ECGs; this method improves sensitivity and specificity of the current technique used to identify the presence of a drug called moxifloxacin. This drug is used as a positive control compound in clinical studies investigating the level of drug cardiotoxicity related to the ventricular repolarization process. We describe a new technology and the preliminary results revealing the superiority of our technique in comparison to QT interval prolongation. This technology may play an important role in the future of drug-safety assessment.